Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

NCT02951845 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped JNJ-54416076 program has been stopped for strategic business reasons.

Conditions

Healthy

Interventions

DRUG: JNJ-54416076 (Oral Suspension)
DRUG: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
DRUG: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)

Sponsor

Janssen Research & Development, LLC